Biohaven has granted Ono Pharmaceutical an exclusive license to develop and commercialize its MoDE pan IgG degrader portfolio, including the lead drug BHV-1300, in Japan, South Korea, Taiwan, and ASEAN countries. Biohaven will receive up to $100 million in near-term payments, including $80 million upfront and $20 million upon a milestone, plus about 20% royalties on net sales. BHV-1300 is in Phase 3 trials for Graves' disease and has shown promising results in reducing disease-causing antibodies and normalizing thyroid hormones. This collaboration leverages Biohaven's innovative Yale-originated MoDE platform and Ono's regional development and commercial expertise, marking a significant step for extracellular protein degrader therapies in Asia.
Biohaven's strategic licensing deal with Ono Pharma for IgG degraders provides context for health-sector trading on Pluang. As of Oct 08, 2026 15:02 WIB, 34 of 100 health stocks rose while 59 fell. Among notable movers, Novavax Inc (NVAX) traded at USD 11.09 with 79% sell orders and a typical hold time of 59 days, contrasting with Twist Bioscience Corp (TWST) at USD 154.01, which saw 97% buy orders and a shorter hold time of 27 days. Koninklijke Philips NV (PHG) had 100% buy orders at USD 23.84 and a longer hold time of 84 days, illustrating varied investor engagement across health stocks on Pluang.
CIQ has released Fuzzball 4.3, a platform that enables enterprises to deploy validated open-weight AI models and agents on their existing GPU infrastructure with a single command. This update simplifies operationalizing AI by automatically connecting...
As of September 30, 2026, Societe Generale's share capital consists of 739,264,232 shares with a total of 821,169,560 voting rights. The bank highlights its strong global presence with 110,000 employees serving 27 million clients across 58 countries....
Weyerhaeuser's stock recently dropped to a new 52-week low of $18.31, trading around $18.51, reflecting market pressure. Analysts have mixed views: Seaport Global lowered its price target to $30, Raymond James upgraded to "strong buy" with the same t...
Canadian Utilities and Emera have agreed to merge as equals, creating a larger utility and energy infrastructure company. RBC Capital maintains a 'Sector Perform' rating on Canadian Utilities, indicating expected performance in line with the sector. ...
Domino's Pizza is set to report its Q3 earnings on October 13, 2026, with analysts forecasting earnings per share between $4.33 and $4.36 and revenue around $1.17 billion, a 1.6% increase year-over-year. Investors will watch closely how promotional d...
